retatrutide type 2 diabetes trial results 2024 2025 Retatrutide, a TRIPLE agonist (GLP1, GIP, glucagon), just released phase demonstrating 25% weight loss in half of people with #obesity. This amount of weight loss has not been accomplished Positive Top-line Results for Retatrutide

2 mg every week for 4 weeks, then 4 mg every week for the rest of the time 3

Ozempic dosing schedule Ozempic follows a relatively straightforward titration

New generation, highly potent GLP-1 [drugs] with higher efficacy in weight reduction may convey an even greater advantage in reducing the risk of obesity-related cancers, but future research is needed to make sure that these drugs do not increase the risk for non-obesity-related cancers, he added in a news release

Glycogen synthase kinase-3beta haploinsufficiency mimics the behavioral and molecular effects of lithium

For individuals struggling with obesity, Semaglutide can be an effective treatment option

Its FDA-approved for weight loss and management as a once-weekly injection (Wegovy) and a once-daily tablet ( Wegovy pill )